Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio
HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
HQ Team September 2, 2023: Novartis, one of the world’s top five pharmaceutical companies by revenue, has filed a lawsuit against two US.
HQ Team June 3, 2023: Novartis breast cancer drug Kisqali cut the risk of recurrence of the disease by more than 25% in.
HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.